The mTOR (mechanistic target of rapamycin) is a master regulator of several crucial cellular
processes, including protein synthesis, cellular growth, proliferation, autophagy, lysosomal …

Initiation and progression of atherosclerosis depend on local inflammation and
accumulation of lipids in the vascular wall. Although many cells are involved in the …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Advances in maintenance immunosuppression over the past three decades have improved
solid organ transplantation outcomes dramatically. Uninterrupted access to …

CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …

Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after
heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant …

Immunosuppressive medications are widely used to treat patients with neoplasms,
autoimmune conditions and solid organ transplants. Key drug classes, namely calcineurin …

Heart transplantation (HTx) has become standard treatment for selected patients with end-
stage heart failure. Improvements in immunosuppressant, donor procurement, surgical …

The advancement in pharmaceutical research has led to the discovery and development of
new combinatorial life-saving drugs. Rapamycin is a macrolide compound produced from …

Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac
transplantation. Recent insights have underscored the fact that innate and adaptive immune …